Determinar pyrilinks-D de pacientes con osteoporosis post terapia con alendronato durante un año
Fecha
2013
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Carrera de Tecnología Médica
Resumen
Osteoporosis enfermedad que disminuye cantidad de minerales en hueso, perdiendo fuerza parte de hueso trabecular y reduciéndose zona cortical por defecto en absorción del calcio producido por falta de manganeso, que los vuelve quebradizos y susceptibles de fracturas y de microfracturas, y puede llevar a aparición de anemia o ceguera. Densidad mineral de los huesos se establece mediante densitometría ósea. Pyrilinks-D es abreviatura de Deoxipiridinolina, componente del colágeno tipo I, que está siempre presente en huesos. Cuando este elemento se encuentra, sin metabolizar en orina indica que se están perdiendo de calcio a ritmo más rápido de que están absorbiendo para construir nuevo tejido óseo. Algunos de los beneficios de esta nueva prueba con preferencia a gammagrafía ósea DEXA son no utiliza ningún tipo de radiación dañina, tiene resultados rápidos, no tienen que esperar varios meses o años para que resultados de pruebas que viene, prueba es predictor más exacto de huesos fractura. Las evaluaciones realizadas a las pacientes en edad menopáusica de 45 a 60 años de edad indican que la mayor parte de ellas son de vida sedentarias, condición que se correlaciona negativamente con la presencia de factores de riesgo a la enfermedad. Se ha llevado a cabo este estudio clínico para establecer la seguridad y eficacia del ensayo pyrilinks-D en el seguimiento de los cambios del DPD urinario asociado a la terapia antiresorptiva con amino-bifosfonatos. Los resultados de este estudio indican que el test de pyrilinks-D es seguro y efectivo para el seguimiento de la terapia antiresoptiva con amino-bifosfonatos en pacientes diagnosticados con osteoporosis.
Osteoporosis disease that decreases the amount of minerals in bone, losing part of trabecular bone and reducing cortical area by default in calcium absorption caused by lack of manganese, which makes them brittle and susceptible to fractures and microfractures, and can lead to the appearance of anemia or blindness Bone mineral density is established by bone densitometry. Pyrilinks-D is an abbreviation for Deoxipyridinoline, a component of type I collagen, which is always present in bones. When this element is found, without metabolizing in urine it indicates that they are losing calcium at a faster rate than they are absorbing to build new bone tissue. Some of the benefits of this new test with preference to DEXA bone scintigraphy are that it does not use any harmful radiation, has fast results, does not have to wait several months or years for the next test results, test is a more accurate predictor of bones fracture. Evaluations carried out on menopausal patients aged 45 to 60 years indicate that most of them are sedentary, a condition that correlates negatively with the presence of risk factors for the disease. This clinical study has been carried out to establish the safety and efficacy of the pyrilinks-D trial in the follow-up of changes in the urinary DPD associated with antiresorptive therapy with amino bisphosphonates. The results of this study indicate that the pyrilinks-D test is safe and effective for the follow-up of antirepressant therapy with amino bisphosphonates in patients diagnosed with osteoporosis.
Osteoporosis disease that decreases the amount of minerals in bone, losing part of trabecular bone and reducing cortical area by default in calcium absorption caused by lack of manganese, which makes them brittle and susceptible to fractures and microfractures, and can lead to the appearance of anemia or blindness Bone mineral density is established by bone densitometry. Pyrilinks-D is an abbreviation for Deoxipyridinoline, a component of type I collagen, which is always present in bones. When this element is found, without metabolizing in urine it indicates that they are losing calcium at a faster rate than they are absorbing to build new bone tissue. Some of the benefits of this new test with preference to DEXA bone scintigraphy are that it does not use any harmful radiation, has fast results, does not have to wait several months or years for the next test results, test is a more accurate predictor of bones fracture. Evaluations carried out on menopausal patients aged 45 to 60 years indicate that most of them are sedentary, a condition that correlates negatively with the presence of risk factors for the disease. This clinical study has been carried out to establish the safety and efficacy of the pyrilinks-D trial in the follow-up of changes in the urinary DPD associated with antiresorptive therapy with amino bisphosphonates. The results of this study indicate that the pyrilinks-D test is safe and effective for the follow-up of antirepressant therapy with amino bisphosphonates in patients diagnosed with osteoporosis.
Descripción
PDF
Palabras clave
Osteoporosis, Desintometría ósea, Fracturas óseas, Ecuador, Pyrilinks-D, Alendronato, Cantón Guayaquil